Trends among pathogens reported as causing bacteraemia in England, 2004–2008  by Wilson, J. et al.
Trends among pathogens reported as causing bacteraemia in England,
2004–2008
J. Wilson1, S. Elgohari1, D. M. Livermore1, B. Cookson1, A. Johnson1, T. Lamagni1, A. Chronias2 and E. Sheridan1
1) Health Protection Agency, Centre for Infections, 2) Information Department, Royal Free NHS Hospital Trust, Pond Street, London, UK
Abstract
The Health Protection Agency in England operates a voluntary surveillance system that collects data on bacteraemias reported by over
90% of laboratories in England. Trends in causative microorganisms reported between 2004 and 2008 were analyzed using a generalized
linear model with a log link function for Poisson distribution. In 2008, 101 276 episodes of bacteraemia were reported; a rate of 189
per 100 000 population. More than one-half occurred in those aged over 65 years and males. The most common organisms reported
were Escherichia coli (23%), coagulase-negative staphylococci (CNS) (16.9%) and Staphylococcus aureus (11.4%). Between 2004 and 2008,
E. coli bacteraemia increased by 33% (p <0.001); the species now accounts for more than 30% of bacteraemia in those aged over
75 years. There also were signiﬁcant increases in bacteraemia caused by other Gram-negative pathogens and marked seasonal variation.
Bacteraemia caused by S. aureus increased until 2005, with a decline after 2006 (p <0.001) entirely due to methicillin-resistant strains.
CNS bacteraemia have declined signiﬁcantly since 2007. The renewed dominance of Gram-negative pathogens as major causes of bac-
teraemia in England is of particular concern because they are associated with a high morbidity and increasing resistance to antibiotics.
Further investigation of the underlying causes and prevention strategies is a public health priority. Recent declines in methicillin-resistant
S. aureus bacteraemia have not been reﬂected in other pathogens, including methicillin-susceptible S. aureus.
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Introduction
Bacteraemias are a signiﬁcant cause of morbidity and mor-
tality [1,2]. They may result from microorganisms intro-
duced to the bloodstream via an invasive device, or be
secondary consequences of infections at another body site;
both types are commonly associated with healthcare. The
epidemiology of bacteraemia is likely to be inﬂuenced by a
range of factors, including advances in medical care
and the use of more invasive operative and diagnostic
technologies and therapeutics, increases in longevity, and
changes in prevalence of chronic diseases, such as renal or
hepatic failure. All these factors increase vulnerability to
bacteraemia.
In England the Health Protection Agency (HPA) has oper-
ated a voluntary system for the capture of data on microor-
ganisms of clinical signiﬁcance, including those isolated from
blood cultures, since the 1970s, with the aim of gathering
information on temporal trends and epidemiology. Electronic
data capture systems were introduced in the early 1990s,
and data are now collected from pathology systems and
transmitted from microbiology laboratories to the national
database (LabBase2) using software that transforms them
into the required format. Laboratory mergers and reconﬁgu-
rations have resulted in an overall reduction in the number
of laboratories during the last decade and, by 2008, virtually
all laboratories in England were reporting to the database,
with the vast majority using automated data transfer systems
[3]. The reporting laboratories provide services for all types
of facilities, including university and general hospitals and
specialist or regional centres. Participating laboratories
submit data on all positive blood cultures, although, where
possible, they exclude those considered not to be clinically
signiﬁcant. Despite some caveats on data completeness and
laboratory changes over this time, these data provide a very
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comprehensive national picture of the relative importance
and trends among pathogens responsible for bacteraemia [4].
In this analysis, we have addressed the potential effect on
trends of changes in case ascertainment over time by identi-
fying a core set of laboratories that had established auto-
mated data transfer systems and submitted consistent
volumes of data between 2004 and 2008. These data there-
fore represent the best available estimate of national trends
in pathogens causing bacteraemia.
Materials and Methods
Microbiological data for bacteraemia reported by all 210 hos-
pital laboratories in England that had submitted data between
2004 and 2008 were extracted from LabBase2. Repeat cul-
ture reports of the same organism taken from the same
patient within 14 days were identiﬁed using probabilistic
matching rules based on the organism identiﬁed, NHS num-
ber and other identiﬁers, and were removed from the analy-
sis. If more than one pathogen was isolated from the same
blood culture, the pathogens were reported individually but
counted as a single episode of bacteraemia. Whilst laborato-
ries are asked to report only cultures related to infections,
in the absence of clinical details about the patient, some epi-
sodes may reﬂect contamination of the specimen by skin
organisms, particularly coagulase-negative staphylococci
(CNS), rather than true infection. We have therefore consid-
ered trends in terms of the proportion of episodes caused
by speciﬁc pathogens adjusted for changes in number of
episodes over time. In 2008, 167 laboratories reported data
on bacteraemia (representing approximately 95% of all
microbiology laboratories in England at this time). These data
were used to evaluate the current prevalence and distribu-
tion of pathogens. Incidence rates by age and sex were calcu-
lated using Ofﬁce for National Statistics mid-year population
estimates for 2008 as the denominator.
A subset of 137 laboratories (65% of the total 210 labora-
tories that had submitted data) that had reported consistently
in each year between 2004 and 2008 was obtained by exclud-
ing sites that had changed from manual to automated report-
ing; had not submitted data in each year; or had submitted
incomplete data in one or more years (as demonstrated by
large ﬂuctuations in number of reports not explicable by
reconﬁguration of services or reporting arrangements). Data
from these 137 laboratories were used to analyze trends in
reported pathogens.
The predominant pathogens were deﬁned at genus or
species level as: Escherichia coli, Staphylococcus aureus, Strepto-
coccus pneumoniae, Enterococcus spp. (including Group D
streptococcus), Klebisella spp., Proteeae (including Proteus
spp., Morganella morganii, Providencia spp.), Pseudomonas spp.,
Enterobacter spp. and coagulase-negative staphylococci (Staph-
ylococus epidermidis, S. saphrophyticus). Other streptococci
were grouped according to the taxonomy described else-
where [5].
Trends were analyzed in STATA, version 9.2 (StataCorp,
College Station, TX, USA) using a generalized linear model
with a log link function for the Poisson distribution, com-
paring proportions between years with an offset to account
for the variability in the total number of organisms per
year. The model was based on a Poisson distribution
(because the data comprised counts of episodes of infec-
tions) and was re-parameterized four times using different
base years to allow rolling 2-year comparisons of the pro-
portions. Incidence rate ratios, with 95% CIs and p-values,
were estimated to determine signiﬁcant changes in the
relative proportion of bacteraemia caused by speciﬁc
organisms.
Results
Rates of bacteraemia and main causative pathogens in 2008
During 2008, 97 195 episodes of bacteraemia were reported
by 167 laboratories, comprising an overall rate of 189 per
100 000 population, ranging from 24 per 100 000 population
in those aged 10–14 years to 857 per 100 000 population in
those aged 75 years or more. More than one-half of the bac-
teraemias occurred in people aged over 65 years, more than
one-third in those aged 75 years or more, and fewer than
10% in children (Fig. 1). The distribution of pathogens by age
group in 2008 (Fig. 1) demonstrated marked differences. In
the younger age groups, Gram-positive pathogens predomi-
nate, with CNS being the most common isolates up to the
age of 44 years.
Bacteraemias occurred more commonly in males, who
accounted for 54% of episodes. The population-based rates
were 23% higher in males than females: 205 per 100 000
population vs. 167.3 per 100 000 population (p <0.001).
Males were less likely than females to have bacteraemia
caused by E. coli (19% compared to 27% of episodes;
p <0.001) but more likely to have bacteraemia caused by
S. aureus (13% vs. 10%; p <0.001) (Table 1).
In 2008, the 12 most common pathogens accounted for
80% of all episodes of bacteraemia reported. E. coli was
the most frequent agent, accounting for 22.5% of all epi-
sodes, followed by CNS (16.9%) and S. aureus (11.6%); a
further 14% of episodes were caused by the other main
Gram-negative pathogens: Klebsiella spp., Pseudomonas
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spp., Enterobacter spp. and Proteeae (Table 2). Eight
thousand three hundred and sixty-nine episodes (9%) were
polymicrobial.
Trends in episodes of bacteraemia between 2004 and 2008
Between January 2004 and December 2008, a total 458 660
episodes of bacteraemia were reported by 210 laboratories.
In the subset of 137 consistently-reporting laboratories,
361 263 episodes of bacteraemia were reported, represent-
ing 79% of all episodes. In this subset, the number of
reported episodes of bacteraemia increased by 15% between
2004 and 2006, but subsequently declined, leaving an overall
increase of 7% between 2004 and 2008 (p <0.001). Over
90% of the recent decline between 2006 and 2008 was asso-
ciated with S. aureus (58% of the decline) and CNS (34%)
(Fig. 2 and Table 2).
Trends in the most common pathogens between 2004 and
2008
In the consistently-reporting laboratories, the 12 most-com-
monly-reported pathogens accounted for 80% of all episodes
of bacteraemia (Fig. 2 and Table 2). E. coli was the most
common pathogen in each of the 5 years, with the number
of reports increasing 32% from 12 579 in 2004 to 16 663 in
2008 (p <0.001) (Table 2). By 2008, the overall proportion
of bacteraemias caused by E. coli was 23%, increasing to
30.5% in the those aged over 75 years, and with a particu-
larly marked increasing trend in this age group (data not
shown). There was a marked seasonal trend both for E. coli
and other Gram-negatives such as Klebsiella spp. and Pseudo-
monas spp., with a peak in the summer (Fig. 2).
Aside from E. coli, there also were signiﬁcant increases in
the numbers of bacteraemias caused by other Gram-negative
pathogens from 2004 to 2008. Those due to Klebsiella spp.
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FIG. 1. Common isolates causing bac-
teraemia in England by age group in
2008 (all laboratories; n = 167)
TABLE 1. Ranking of common pathogens causing bactera-
emia in England in 2008 by sex (all laboratories)
Gender Organism Order
Number of
episodes
% of total
organisms
Male Escherichia coli 1 10 070 19.4
CNS 2 8519 16.4
Staphylococcus aureus 3 6932 13.3
Enterococcus spp. 4 3422 6.6
Klebsiella spp. 5 3282 6.3
Streptococcus pneumoniae 6 2279 4.4
Pseudomonas spp. 7 2210 4.3
Proteeae 8 1732 3.3
Enterobacter spp. 9 1303 2.5
Bacteroides spp. 10 692 1.3
Streptococcus group B 11 690 1.3
Streptococcus (mitis group) 12 609 1.2
Total of 12 most common 41 740 80.3
Other pathogens total 10 240 19.7
Total organisms 51 980 100.0
Female E. coli 1 11 572 26.5
CNS 2 7541 17.3
S. aureus 3 4193 9.6
Klebsiella spp. 4 2328 5.3
Enterococcus spp. 5 2266 5.2
S. pneumoniae 6 2062 4.7
Pseudomonas spp. 7 1462 3.3
Proteeae 8 1021 2.3
Enterococcus spp. 9 902 2.1
Streptococcus group B 10 735 1.7
Bacteroides spp. 11 588 1.3
Streptococcus group A 12 549 1.3
Total of 12 most common 35 219 80.6
Other pathogens total 8484 19.4
Total organisms 43 704 100.0
CNS, coagulase-negative staphylococci
Numbers reported include only those episodes where data on gender were
available
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increased by 14%, Pseudomonas spp. by 24% and Proteeae by
13% (Table 3). Although the proportion of bacteraemia asso-
ciated with these organisms has increased signiﬁcantly over
the whole period, the generalized linear model showed the
trends were not linear for all pathogens. For example, the
Proteeae only increased signiﬁcantly between the years
2006/07 and 2007/08, and Klebsiella spp, although increasing
signiﬁcantly over the 5 years, only showed a signiﬁcant inter-
year increase between 2007 and 2008 (Table 3).
There was a signiﬁcant increase in episodes of CNS
bacteraemia reported between 2004 and 2007 followed by a
signiﬁcant decline between 2007 and 2008, with an overall
rise of 12% between 2004 and 2008 (Fig. 2 and Table 3).
The decline was only apparent for adult patients, not chil-
dren (data not shown).
Reports of bacteraemia caused by S. aureus increased until
2005, but declined by 24% between 2006 and 2008. This decline
was only associated with methicillin-resistant strains: whereas
TABLE 2. Number and proportion of episodes of bacteraemia caused by the most common pathogens (England)
Pathogen
All laboratories (n = 167) Consistently reporting laboratories (n = 137)
2008 2004 2008
% change
in number
of episodes p-valuea
Number of
episodes %
Rate per
100 000
population
Number of
episodes %
Number of
episodes %
Escherichia coli 21 878 22.5 42.5 12579 18.8 16 663 23.3 +32.5 <0.001
CNS 16 443 16.9 32.0 9086 13.5 10 165 14.2 +11.9 0.003
Staphylococcus aureus 11 234 11.6 21.8 11370 17.0 8660 12.1 )23.8 <0.001
Enterococcus spp. 5814 6.0 11.3 4980 8.1 4531 6.3 )9.0 <0.001
Klebsiella spp. 5678 5.8 11.0 3739 5.6 4274 6.0 +14.3 0.004
Streptococcus pneumoniae 4402 4.5 8.6 3616 5.4 3415 4.8 )5.6 <0.001
Pseudomonas spp. 3753 3.9 7.3 2290 3.4 2829 4.0 +23.5 <0.001
Proteeae 2779 2.9 5.4 1859 2.7 2101 2.4 +13.0 0.095
Enterobacter spp. 2225 2.3 4.3 1812 2.4 1653 2.3 )8.8 <0.001
Streptococcus group B 1446 1.5 2.8 879 1.3 1135 1.6 +29.1 <0.001
Bacteroides spp. 1300 1.3 2.5 909 1.4 978 1.4 +7.6 0.932
Streptococcus (mitis group) 1164 1.2 2.3 864 1.3 818 1.1 +4.2 0.011
Total 78 116 80.4 151.8 53 983 80.9 57 222 80.1 +6.0 0.067
Other pathogens 19 079 19.6 37.1 12 704 19.1 14 246 19.9 +12.1 <0.001
Total (all episodes) 97 195 188.9 66 687 71 468 +7.2 <0.001
CNS, coagulase-negative staphylococci
aFrom the generalized linear model with log link function comparing the change in probability of episodes by pathogen for 2008 to the base year 2004 with offset for total
organisms.
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FIG. 2. Trends in total number of reported episodes of bacteraemia in England for all laboratories (n = 210) and for the 12 most common
pathogens in consistently-reporting laboratories (n = 137) between 2004 and 2008.
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the number of episodes and proportion of all bacteraemia
caused by methicillin-susceptible S. aureus (MSSA) increased
signiﬁcantly between 2004 and 2008 (Fig. 3 and Table 3).
In 2004, methicillin-resistant S. aureus (MRSA) accounted for
41% of S. aureus bacteraemia but only 23% by 2008.
Reports of bacteraemia due to Enterococcus spp. declined
by nearly 6% between 2004 and 2008, with signiﬁcant
decreases each year from 2005. Episodes of S. pneumoniae
bacteraemia declined by 6% between 2004 and 2008, tem-
porally associated with the introduction of conjugate vac-
cine to the childhood immunization schedule in England in
2006 [6]. The seasonal variation of episodes of bacteraemia
caused by this pathogen showing the expected winter
peaks is clearly illustrated in Fig. 2. Episodes of bacteraemia
due to group B streptococci increased by 30% between
2004 and 2008, and, by 2008, accounted for 1.6% of all
bacteraemia, with the majority of cases occurring in chil-
dren under 1 year (Fig. 1). Reports of bacteraemias due to
Bacteroides spp. increased signiﬁcantly between 2004 and
2006, but there was no signiﬁcant overall change between
2004 and 2008. Streptococci from the ‘mitis’ group
declined between 2004 and 2008.
TABLE 3. Relative in change in proportion of bacteraemia episodes attributable to a causative pathogen using rolling 2-year
comparisons
2005 vs. 2004 (base) 2006 vs. 2005 (base) 2007 vs. 2006 (base) 2008 vs. 2007 (base) 2008 vs. 2004 (base)
IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value
Coagulase-negative
staphylococci
1.07 1.036–1.096 <0.001 1.06 1.033–1.089 <0.001 1.04 1.013–1.066 0.003 0.89 0.866–0.913 <0.001 1.04 1.015–1.074 0.003
Escherichia coli 1.03 1.003–1.053 0.028 1.02 0.993–1.040 0.174 1.05 1.026–1.073 <0.001 1.13 1.104–1.153 <0.001 1.24 1.208–1.265 <0.001
Klebsiella spp. 0.99 0.951–1.039 0.792 1.02 0.975–1.063 0.411 1.01 0.967–1.052 0.705 1.05 1.002–1.090 0.040 1.07 1.021–1.114 0.004
Staphylococcus aureus 0.95 0.925–0.974 <0.001 0.92 0.897–0.944 <0.001 0.89 0.865–0.913 <0.001 0.92 0.890–0.943 <0.001 0.71 0.691–0.731 <0.001
Methicillin-resistant
S. aureusa
1.00 0.954–1.038 0.824 0.95 0.911–0.993 0.022 0.80 0.761–0.837 <0.001 0.76 0.720–0.809 <0.001 0.58 0.546–0.609 <0.001
Methicillin-sensitive
S. aureusa
1.00 0.969–1.038 0.857 1.03 0.998–1.067 0.069 1.12 1.085–1.160 <0.001 1.10 1.065–1.140 <0.001 1.28 1.236–1.324 <0.001
Streptococcus pneumoniae 1.04 0.997–1.090 0.071 0.88 0.844–0.922 <0.001 0.95 0.907–0.994 0.026 1.01 0.963–1.058 0.691 0.88 0.841–0.923 <0.001
Enterococcus spp. 1.02 0.978–1.056 0.423 1.04 1.001–1.078 0.042 0.92 0.884–0.951 <0.001 0.88 0.843–0.913 <0.001 0.85 0.815–0.884 <0.001
Proteeae (Proteus spp.,
Morganella spp. and
Providencia spp.)
0.93 0.874–0.994 0.032 0.93 0.869–0.988 0.20 1.08 1.013–1.151 0.018 1.13 1.063–1.202 <0.001 1.05 0.991–1.122 0.095
Pseudomonas spp. 1.01 0.954–1.069 0.729 1.06 1.003–1.117 0.040 0.98 0.926–1.029 0.376 1.10 1.048–1.164 <0.001 1.15 1.091–1.218 <0.001
Enterobacter spp. 0.96 0.903–1.028 0.260 1.00 0.938–1.064 0.964 0.94 0.886–1.006 0.074 0.94 0.877–1.002 0.055 0.85 0.796–0.910 <0.001
Streptococcus Group B 1.00 0.911–1.095 0.982 1.11 1.019–1.212 0.017 0.93 0.852–1.009 0.081 1.17 1.075–1.274 <0.001 1.20 1.103–1.316 <0.001
Bacteroides spp. 0.90 0.818–0.985 0.022 0.90 0.818–0.989 0.029 1.26 1.149–1.378 <0.001 0.99 0.905–1.078 0.787 1.00 0.917–1.099 0.932
Streptococcus spp.
(mitis group)
0.93 0.843–1.018 0.111 1.03 0.937–1.128 0.557 0.96 0.877–1.053 0.393 0.97 0.878–1.062 0.471 0.88 0.803–0.972 0.011
All 12 pathogens 1.00 0.993–1.016 0.446 1.00 0.985–1.008 0.511 0.99 0.978–1.001 0.064 1.00 0.988–1.010 0.847 0.99 0.978–1.000 0.067
All other pathogens 0.98 0.957–1.005 0.114 1.02 0.993–1.041 0.173 1.05 1.021–1.069 <0.001 1.00 0.982–1.028 0.698 1.05 1.022–1.072 <0.001
All pathogens
(without offset)
1.08 1.066–1.089 <0.001 1.06 1.048–1.069 <0.001 0.99 0.978–0.998 0.014 0.95 0.942–0.962 <0.001 1.07 1.060–1.083 <0.001
IRR, incidence rate ratio (ratio of proportions between years adjusted for total number of organisms from a generalized linear model).
aBased on all S. aureus isolates with susceptibility tests, adjusted for the total number of S. aureus organisms.
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Location of patient when blood culture were taken based
on consistently reporting laboratories 2004–2008
For the 247 676 (69%) episodes where the location of the
patient when the blood cultures were taken was reported,
the great majority (81%) were in hospital, but 11% were out-
patients (likely reﬂecting patients receiving invasive therapy
such as renal dialysis or chemotherapy) and 5% were found
in accident and emergency cases.
Discussion
During the 1990s, E. coli was the most commonly reported
agent of bacteraemia in England, but reports of S. aureus bac-
teraemia then increased markedly so that, by 2000, it
accounted for over 20% of cases and replaced E. coli as the
leading pathogen [4,7]. This analysis shows that E. coli not
only has re-emerged as the most prevalent agent of bactera-
emia, accounting for almost one-quarter of all episodes by
2008, but also that it has shown sustained signiﬁcant annual
increases since 2004. This trend is particularly evident among
those aged over 75 years, in whom E. coli accounted for
almost one-third of all bacteraemia by 2008, suggesting an
important change in the epidemiology of bacteraemia in Eng-
land.
There appear to be important differences between Europe
and the USA. In many other European countries, E. coli is
also reported as the most common pathogen of bacteraemia
and S. aureus second, whereas, in the USA, S. aureus is far
more common (accounting for more than one-quarter of
episodes) and E. coli second [8]. E. coli bacteraemia is most
likely to be secondary to a focal infection such as urinary
tract, abdominal, hepato- or biliary sepsis, or surgical infec-
tions, although association with central vascular devices has
also been reported [9]. Although some of these cases may
be truly community-acquired, Marschall et al. [10] reported
that in over 80% of patients admitted with Gram-negative
bacteraemia the infection was associated with prior health-
care; in particular, more than two-thirds had been recently
hospitalized or were receiving outpatient treatment such as
haemodialysis or intravenous chemotherapy [10].
The marked increasing trend in bacteraemia caused by
E. coli is of particular concern because the species has shown
sharp recent increases in resistance to important antimicro-
bial agents. A recent detailed analysis of E. coli isolates from a
set of sentinel laboratories in the UK and Ireland demon-
strated striking increases in the prevalence of resistance to
oxyimino-cephalosporins such as ceftoxime and ceftazidime;
from approximately 2% in 2001 to 12% in 2006, ciproﬂoxacin
from 4% in 2000 to 26% in 2006, and gentamicin from 5% in
2001 to 11% in 2006 [11]. Over 80% of the isolates resistant
to oxyimino-cephalosporins were co-resistant to quinolones
and gentamicin. These increases were linked to the emer-
gence and spread of strains producing CTX-M type extended
spectrum b-lactamase and strains with these enzymes are
reportedly carried in the gut of a high proportion of elderly
patients in nursing homes, comprising a major source of
repeat admissions to hospital [12]. Reliance on urinary cathe-
ters for the management of elderly incontinent patients
in hospital, and the continued use of these catheters when
patients are transferred to residential or nursing homes,
may be a contributory factor in E. coli bloodstream infection
[13].
Reported episodes of bacteraemia caused by Gram-nega-
tive pathogens besides E. coli also increased between 2004
and 2008 and these organisms now account for almost one-
half of the twelve commonest pathogens. Bacteraemia due to
Pseudomonas spp., is mostly hospital-acquired, with the geni-
tourinary and respiratory tracts, and intravenous devices,
cited as the most common sources. Except for ciproﬂoxacin,
where almost one-quarter of isolates are resistant, antimi-
crobial resistance rates remain low among bloodstream
pseudomonas isolates in England [14]. Nevertheless, they are
associated with a case-fatality rate of over 30% [15]. Approx-
imately two-thirds of bacteraemia caused by Klebsiella spp.
are reported as hospital-acquired, with intravenous devices
and the genitourinary tract being common sources [16].
These organisms have also shown dramatic increases in anti-
microbial resistance since 2001, with mechanisms similar to
E. coli [14]. The urinary tract is the major source of proteeae
bacteraemias, with many of them linked to the use of long-
term urinary catheters [14]. The marked increase in bactera-
emia associated with E. coli in particular, but also other
Gram-negative pathogens, in the summer has been recently
observed by Al-Hassan et al. [17]. Because these bacteraemia
are commonly associated with urinary tract infections and at
least one-third occurred in the very elderly, dehydration
linked to deﬁcits in thirst recognition may be a possible con-
tributory factor [18].
The data show a signiﬁcant decrease in S. aureus as a
cause of bacteraemia, and, by 2008, this organism had
become only the third most common agent, accounting for
12% of episodes. This decline was entirely due to reductions
in MRSA because the numbers of episodes of bacteraemia
due to MSSA were not signiﬁcantly changed over this period.
The proportion of S. aureus resistant to meticillin declined
markedly between 2004 and 2008 and MRSA accounted for
only approximately 3% of all bacteraemia in 2008, compared
to 6% in 2004. Indeed, both the increase in S. aureus as a
cause of bacteraemia in the early 2000s, and subsequent
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decline in the last 5 years, were associated with MRSA [19].
Major national initiatives targeted at MRSA bacteraemia in
England since 2004 [3] appear to have been successful, but
do not appear to have had any appreciable impact on MSSA.
A key component of this MRSA reduction strategy has been
the prevention of intravenous-device associated infections
and it might be expected that these initiatives would have
also have prevented MSSA infections. It is therefore possible
that targeted detection and decolonization of patients carry-
ing MRSA have accounted for a greater part of the effect. A
further complicating factor is that recent data suggest a
decline starting before 2001, and therefore prior to the
major control programme, in one of the two major hospital
MRSA strains (EMRSA-16), perhaps indicating an effect predi-
cated on natural biological trends [20]. At least part of the
explanation for the differential effect of these preventative
strategies may therefore lie in factors that underpin the eco-
logical success of different strains of S. aureus. Certainly, the
emergence and disappearance of MRSA strains for reasons
that remain largely obscure is not a new phenomenon, as
exempliﬁed by the virtual disappearance of the once-preva-
lent EMRSA-1 and 3 strains [21].
By contrast to S. aureus, reports of CNS increased from
2004 to 2007 before declining in 2008. Although universal
skin commensals, CNS are important pathogens in health-
care-associated infection, especially device-associated bactera-
emia in neonates, haematology and oncology patients, and
cause deep surgical infection in surgical implants [22,23]. The
more recent decline is interesting because it was counter to
the previous trend. It may have been inﬂuenced by changes in
practice in relation to taking of blood cultures associated with
the publication of national guidance in 2006 [24]. This guid-
ance aimed to improve the technique of taking blood cultures
in order to minimize contamination with skin organisms.
Alternatively, because CNS are commonly associated with
central vascular devices, this decline may also be linked to the
other national initiatives aimed at preventing MRSA infections
[3]. Curiously, the decline was most marked in patients aged
over 75 years and was not apparent in children [6].
The trends among pathogens causing bacteraemia may be
inﬂuenced by aspects of healthcare treatment and delivery but,
currently, there are few data on the factors contributing to
bacteraemia, the primary sources of infection and the extent
to which these infections can be prevented. In more than 80%
of episodes, the specimens were reported as being taken in
hospital patients, although it is not possible to determine the
source of the primary infection, or whether they were associ-
ated with hospital care. Moreover, with changes in the delivery
of healthcare and shorter lengths of hospital stay, the distinc-
tion between hospital- and community-acquired bacteraemias
is being eroded because many of those admitted with bactera-
emia have recently received healthcare [10,25]. Although total
episodes of bacteraemia reported to the HPA have increased
each year since the early 1990s, it has been difﬁcult to distin-
guish the extent to which this reﬂected an increased participa-
tion in this voluntary surveillance system rather than a real
increase [4]. In this analysis, the effect of variation in case
ascertainment was minimized by focusing on laboratories
reporting consistently over the 5-year period. Although the
overall number of blood culture reports from these laborato-
ries has decreased since 2006, much of this decrease was
attributable to CNS and MRSA, whereas the number and
proportion of episodes of bacteraemia due to Gram-negative
pathogens has increased. Moreover, although there may have
been changes in blood culture taking practice during this time,
it is difﬁcult to see how these might have inﬂuenced the data
presented because the common pathogens found, apart from
CNS, would be expected to represent clinical infections if
recovered from blood. In addition, the analysis of trends has
focused on independent changes in proportions of speciﬁc
pathogens and accounted for the numbers of episodes
reported in each year. The data presented are also unlikely to
be affected by misclassiﬁcation bias because all laboratories in
England must be accredited; a process that involves checking
the quality of diagnostic methods.
The recent declines in MRSA bacteraemia may demon-
strate the potential impact of surveillance and control initia-
tives. However, these have not had an apparent positive
collateral effect on other pathogens causing bacteraemia, nor
even on MSSA. In the last 2 years, there have been national
shifts in England away from hospital-prescribing of cephalo-
sporins and quinolones, predicated on concerns about Clos-
tridium difﬁcile, and these are likely to bring different
selection pressures and challenges in the future. The growth
of Gram-negative pathogens as agents of bacteraemia has
also been reported by other countries and in speciﬁc
patients groups. It is of particular concern because these
organisms are associated with both a high mortality and
increasing resistance to antimicrobial agents, particularly
cephalosporins and quinolones, but increasingly also carba-
penems [11,14,26–29]. Further investigation of the factors
precipitating these infections and effective strategies for their
prevention should be a major public health priority.
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